

Name of the Company **PHARMAIDS PHARMACEUTICALS LIMITED**

Statement of Profit and Loss for the period ended 30th September, 2017

Rs. in lakhs

	Particulars	Note No.	Qtr. Ended Unaudited 30.09.2017	Qtr. Ended Audited 30.06.2017	Qtr. Ended Unaudited 30.09.2016	Year to date figures for current period ended 30.9.2017	Year to date figures for previous period ended 30.9.2016	Year Ended Audited 31.03.2017
I	Revenue From Operations		4.90	19.58	31.18	24.48	65.38	120.25
II	Other Income		0.40	-	-	0.40	0.04	1.01
III	Total Income (I+II)		5.30	19.58	31.18	24.88	65.42	121.26
IV	EXPENSES							
	Cost of materials consumed		-	2.67	1.29	2.67	4.48	64.49
	Purchases of Stock-in-Trade		4.50	2.63	14.41	7.13	24.64	-
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress		(0.52)	21.19	(0.73)	20.67	7.22	2.95
	Employee benefits expense		1.62	3.51	5.48	5.13	11.46	16.63
	Finance costs		0.03	0.02	1.48	0.05	2.85	4.01
	Depreciation and amortization expense		0.02	-	1.96	0.02	3.92	6.37
	Other expenses		6.88	7.98	12.09	14.86	17.50	70.53
	Total expenses (IV)		12.53	38.00	35.98	50.53	72.07	164.98
V	Profit/(loss) before exceptional items and tax (III- IV)		(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	(43.72)
VI	Exceptional Items				-	-	-	51.97
VII	Profit/(loss) before tax (V+VI)		(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	8.25
VIII	Tax expense:							
	(1) Current tax Adj. of earlier year		1.75	-	-	1.75	-	-
	(2) Deferred tax		-	-	-	-	-	(2.72)
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
X	Profit/(loss) from discontinued operations		-	-	-	-	-	-
XI	Tax expense of discontinued operations		-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
XIV	Other Comprehensive Income		-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		-	-	-	-	-	-
XVI	Earnings per equity share (for continuing operation):		-	-	-	-	-	-
	(1) Basic		(0.26)	(0.54)	(0.14)	(0.80)	(0.20)	0.32
	(2) Diluted		(0.26)	(0.54)	(0.14)	(0.80)	(0.20)	0.32
XVII	Earnings per equity share (for discontinued operation):							
	(1) Basic							
	(2) Diluted							
XVII I	Earnings per equity share (for discontinued & continuing operations)							
	(1) Basic							
	(2) Diluted							





Directors of the Company at their meeting

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 15th November, 2017. 2. The Un-Audited Financial Results for the Quarter ended 30th Sept, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only 5) Provision for Income Tax and Deferred Tax will be made at the end of the Financial year.

**Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2017 and year ended 31 March 2017 is as follows:**

Particulars	Quarter Ended			Six months Ended		Year ended
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Net profit for the period as per Ind AS	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Other Comprehensive Income	-	-	-	-	-	-
Total Comprehensive Income for the period as per Ind AS	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97

**For PHARMAIDS PHARMACEUTICALS LIMITED**

For Pharmaids Pharmaceuticals Limited

**DR. GHISULAL JAIN**  
**MANAGING DIRECTOR**  
Managing Director

Place : Hyderabad

Date : 15-11-2017

For RAKESH S. JAIN & ASSOCIATES  
CHARTERED ACCOUNTANTS

**B. Ramesh Kumar**  
(B. RAMESH KUMAR)  
PARTNER  
M.No: 200304



Name of the Company **PHARMAIDS PHARMACEUTICALS LIMITED**  
 Balance Sheet as at 30th September 2017

(Rs in Lakhs)

	Particulars	Note No.	Figures as at the end of 30.09.2017	Figures as at the end of 31.03.2017
	1	2	3	4
<b>1 ASSETS</b>				
<b>Non-current assets</b>			0.31	-
(a) Property, Plant and Equipment			-	-
(b) Capital work-in-progress			-	-
(c) Investment Property			-	-
(d) Goodwill			-	-
(e) Other Intangible assets			-	-
(f) Intangible assets under development			-	-
(g) Biological Assets other than bearer plants			-	-
(h) Financial Assets			-	-
(i) Investments			-	-
(ii) Trade receivables			-	-
(iii) Loans			-	-
(iv) Others (to be specified)			-	-
(i) Deferred tax assets (net)			34.67	37.95
(j) Other non-current assets			-	-
<b>2 Current assets</b>			1.12	24.46
(a) Inventories			-	-
(b) Financial Assets			-	-
(i) Investments			62.37	78.77
(ii) Trade receivables			19.29	8.17
(iii) Cash and cash equivalents			33.38	52.70
(iv) Bank balances other than (iii) above			-	-
(v) Loans			-	-
(vi) Others (to be specified)			-	-
(c) Current Tax Assets (Net)			-	-
(d) Other current assets			-	-
<b>Total Assets</b>			151.14	202.05
<b>EQUITY AND LIABILITIES Equity</b>			336.31	336.31
(a) Equity Share capital			(220.93)	(193.53)
(b) Other Equity			-	-
<b>LIABILITIES</b>				
<b>1 Non-current liabilities</b>				
(a) Financial Liabilities			9.26	9.26
(i) Borrowings			-	-
(ii) Trade payables			-	-
(iii) Other financial liabilities (other than those specified in item (b), to be specified)			-	-
(b) Provisions			-	-
(c) Deferred tax liabilities (Net)			-	-
(d) Other non-current liabilities			-	-
<b>2 Current liabilities</b>				
(a) Financial Liabilities			2.65	2.65
(i) Borrowings			23.24	44.78
(ii) Trade payables			-	-
(iii) Other financial liabilities (other than those specified in item (c))			-	-





Date :

### **LIMITED REVIEW REPORT**

To  
**The Board of Directors,  
M/s Pharmaids Pharmaceuticals Limited,  
Hyderabad.**

We have reviewed the accompanying statement of unaudited financial results of **Pharmaids Pharmaceuticals Limited** for the Quarter ended 30<sup>th</sup> September, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Management has informed to us being quarterly closing, the company has not accounted for taxes on income i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.**

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For RAKESH S. JAIN AND ASSOCIATES**  
Chartered Accountants  
Firm Registration No. 010129S

Date: 15-11-2017  
Place: Hyderabad.

  
**B. RAMESH KUMAR**  
Partner  
M. No. 200304